Navigation Links
TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
Date:11/1/2012

WALTHAM, Mass. Nov. 1, 2012 TESARO, Inc. (Nasdaq: TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

TSR-011 is an orally available ALK inhibitor (targeted anti-cancer agent) that will be studied in patients, including non-small cell lung cancer (NSCLC) patients, with ALK+ tumors. TESARO plans to expand the Phase 1/2 clinical trial of TSR-011 to multiple clinical trial sites in the U.S. and Europe.

"TSR-011 has the profile of a promising targeted anti-cancer agent and we are enthusiastic about the opportunity to investigate its potential in patients," said Dr. Glen Weiss, Director of Thoracic Oncology at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and Clinical Associate Professor at TGen.

Following identification of the maximum tolerated dose of TSR-011 in patients with advanced cancer during the dose escalation phase of the trial, TESARO plans to evaluate TSR-011 in three parallel cohorts of patients in the phase 2 portion: those with ALK+ NSCLC who have not been previously treated with ALK inhibitors, those with NSCLC who have progressed during treatment with other ALK inhibitors, and those with other tumor types expressing ALK.

"We are very pleased to have progressed TSR-011 into a human clinical trial and look forward to identifying a dose that may be utilized in the expansion phase of the study which will assess both the safety and efficacy of the compound," said Mary Lynne Hedley, Ph.D., TESARO's President and Chief Scientific Officer. "ALK is a key driver of subsets of NSCLC, and may also contribute to the growth of neuroblastoma, lymphoma and other cancers. In order to maximize the commercial potential of TSR-011, we plan to study TSR-011 in multiple treatment and tumor settings."

About Anaplastic Lymphoma Kinase and Non-Small Cell Lung Cancer

ALK gene fusions that result in constitutive activation of ALK are associated with sub-sets of certain cancers including non-small cell lung cancer (NSCLC). Abnormal ALK proteins are also associated with sub-populations of other cancers including lymphoma and neuroblastoma. ALK is generally not expressed in normal adult tissue and therefore represents a promising molecular target for the development of a cancer therapeutic.

According to the American Cancer Society, over 1.6 million new lung cancer cases are identified worldwide annually, of which over 200,000 of these new lung cancer cases are in the United States. Lung cancer is the leading cause of cancer death in men and the second leading cause of cancer death in women. Lung cancer is typically divided into two groups based upon the histologic appearance of the tumor cellssmall cell and non-small cell lung cancer, each of which is treated with distinct chemotherapeutic approaches. According to the American Cancer Society, NSCLC accounts for approximately 85% of lung cancer cases, with approximately 75% of these patients being diagnosed with metastatic or advanced disease. Despite the introduction of new therapies patients with locally advanced or metastatic NSCLC have five-year survival rates of just 24% and 4%, respectively, according to the Surveillance Epidemiology and End Results program of the National Cancer Institute. ALK is believed to be a key driver of tumor development in approximately 5% of all NSCLC patients.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
2. Biology professor secures grant to save West Virginias primary natural history collection
3. Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium
4. Scientific meeting at Virginia Tech will make more than $2 million economic impact
5. Old deeds, witness trees offer glimpse of pre-settlement forest in West Virginia
6. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
7. Embryonic development protein active in cancer growth
8. BRG1 mutations confer resistance to hormones in lung cancer
9. Genetic variation in East Asians found to explain resistance to cancer drugs
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. Marshall University study may lead to new treatments for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):
(Date:7/17/2017)... ... July 17, 2017 , ... Neurodevelopmental disorders (NDDs) are clinically ... clinical features. The advancement of targeted next-generation sequencing (NGS) has been instrumental in ... , However, designing a custom panel for disease research requires hours of ...
(Date:7/16/2017)... N.J. (PRWEB) , ... July 16, 2017 , ... ... laboratory equipment and analytical instruments announced the launch of its new line of ... are ideal for applications that require CO2 and humidity for optimal cell growth ...
(Date:7/14/2017)... ... July 14, 2017 , ... Diagenode and PreOmics ... to clean peptides for mass spectrometry (MS) analysis combining the PreOmics in-StageTip Kit ... Kit is based on proprietary technology that contains optimized buffer systems permitting ultrafast ...
(Date:7/13/2017)... ... July 13, 2017 , ... ... Inc. (FITCI), has experienced robust growth in the past year after an intensive ... launched several Entrepreneurial Acceleration Programs and expanded its board of directors to revitalize ...
Breaking Biology Technology: